Projects per year
Abstract / Description of output
Background: Single patient or ‘n-of-1’ trials are a pragmatic method to achieve optimal, evidence-based treatments for individual patients. Such trials could be particularly valuable in chronic, heterogeneous, difficult to treat illnesses such as schizophrenia.
Aim: We aimed to identify how often, and in what way, n-of-1 trials have been used in schizophrenia.
Method: We performed a systematic search in the major electronic databases for studies adopting n-of-1 methodology in schizophrenia, published in English from the start of records until the end of January 2017.
Results: We identified six studies meeting inclusion criteria. There was wide variability in study methodology and analysis. Each trial reported positive outcomes for their respective intervention, but all studies were at high risk of bias.
Conclusions: In conclusion, n-of-1 trials are currently under-utilised in schizophrenia. Existing trials suggest the method is well tolerated and potentially effective in achieving optimal treatments for patients, but more standardised methods of design, execution and analysis are required in future trials.
Declarations of interest: SML has received grants and personal fees from Janssen, and personal fees from Otsuka and Sunovion, in the past three years, outside the submitted work. The other authors have no conflicts of interest to declare.
Aim: We aimed to identify how often, and in what way, n-of-1 trials have been used in schizophrenia.
Method: We performed a systematic search in the major electronic databases for studies adopting n-of-1 methodology in schizophrenia, published in English from the start of records until the end of January 2017.
Results: We identified six studies meeting inclusion criteria. There was wide variability in study methodology and analysis. Each trial reported positive outcomes for their respective intervention, but all studies were at high risk of bias.
Conclusions: In conclusion, n-of-1 trials are currently under-utilised in schizophrenia. Existing trials suggest the method is well tolerated and potentially effective in achieving optimal treatments for patients, but more standardised methods of design, execution and analysis are required in future trials.
Declarations of interest: SML has received grants and personal fees from Janssen, and personal fees from Otsuka and Sunovion, in the past three years, outside the submitted work. The other authors have no conflicts of interest to declare.
Original language | English |
---|---|
Journal | The British Journal of Psychiatry |
Early online date | 10 May 2018 |
DOIs | |
Publication status | E-pub ahead of print - 10 May 2018 |
Fingerprint
Dive into the research topics of 'The Application of N-of-1 Treatment Trials in Schizophrenia: A Systematic Review'. Together they form a unique fingerprint.Projects
- 2 Finished
Profiles
-
Katie Marwick
- Deanery of Clinical Sciences - Senior Clinical Research Fellow in Psychiatry
- Centre for Clinical Brain Sciences
- Edinburgh Neuroscience
Person: Academic: Research Active